Click here for slides on this topic


Prediabetes

A condition in which blood sugar is high, but not high enough to be diagnosed as type 2 diabetes.
The following content matched the glossary term: Prediabetes

AACE 2015 guidelines Diabetes Diagnosis

Top

Summary of recommendations for screening and diagnosing type 2 diabetes from the 2015 AACE guidelines. 

Managing the Patient With Type 2 Diabetes and Heart Failure

Top

.style1 FONT FAMILY Arial, Helvetica, sans serif COLOR #004685

NDEI.org Expert Commentary on Type 2 Diabetes Prevention in SEQUEL from Vivian Fonseca

Top

NDEI Education Council Member Vivian A. Fonseca, MD, comments on type 2 diabetes prevention in a substudy of SEQUEL: “Weight loss alone may be an option to prevent type 2 diabetes”

Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release

Top

Exclusive! Expert commentary from Vivian A. Fonseca, MD, on SEQUEL. Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014;37:912-921.

ADA 2016 Children & Adolescents

Top

Recommendations for treating and managing diabetes in children from the 2016 ADA guidelines

American Diabetes Association (ADA)/American Geriatrics Society (AGS) Guidelines 2012

Top

Diabetes management guidelines for older adults from the American Diabetes Association (ADA)/American Geriatrics Society (AGS) 

Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults

Top

Neeland IJ, Turer AT, Ayers CR, Powell Wiley TM, Vega GL, Farzaneh Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308(11):1150-1159. The risk of type 2 diabetes mellitus is heterogeneous among obese individuals. Factors that discriminate prediabetes or diabetes risk within this population have not been well characterized.

SEQUEL: Longer-Term Safety, Efficacy of Phentermine + Topiramate for Weight Reduction Among Overweight or Obese Individuals with Cardiometabolic Disease

Top

Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297-308. The SEQUEL study, an extension of the CONQUER study,1 was a double-blind, placebo-controlled study that evaluated the longer-term efficacy and safety of once-daily, controlled-release phentermine plus topiramate, as an adjunct to lifestyle modification, among overweight and obese subjects with cardiometabolic disease.

CONQUER: Safety, Efficacy of Phentermine + Topiramate for Weight Reduction Among Overweight or Obese Individuals with Weight-Related Comorbidities

Top

Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341-1352. The CONQUER study was a randomized, double-blind, placebo-controlled study that evaluated the safety and efficacy of once-daily, controlled-release phentermine plus topiramate for weight reduction among those who were overweight or obese and had weight-related comorbidities.

Fonseca Commentary

Top

ORIGIN: The Effects of Insulin Glargine and Omega-3 Fatty Acids on Cardiovascular Death in Diabetes or Prediabetes. NDEI.org Education Council Member Vivian A. Fonseca, MD, provides expert commentary on the clinical implications of the ORIGIN omega-3 trial results.

1 2 Next 

Slide Library Results

Search Results for: Prediabetes Slides Found: 39
Prevalence of IFG in Nondiabetic US Adolescents (Aged 12–19 Yrs)
Prevalence of IFG, IGT, and Prediabetes by Cardiometabolic Risk Factors
Prevalence of IFG, IGT, and Prediabetes According to a Combination of Central Obesity and Hyperinsulinemia
Whitehall II: Conclusion
DPPOS Substudy: Effect of Regression from Prediabetes to NGR on Diabetes Risk
DPPOS Substudy: NGR Status and Risk Reduction
DPPOS Substudy: NGR Predictors During DPPOS
DPPOS Substudy: Additional Outcomes
CONQUER: Design
CONQUER: Randomization and Endpoints
SEQUEL: Design Extension of CONQUER Study
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Recommendations for Care and Treatment (1 of 3)
AHA/ACC/TOS Obesity Guidelines: Assessing BMI & Determining Readiness for Lifestyle Changes
SEQUEL Subanalysis: Percent Weight Loss from Baseline at Wk 108 Primary Endpoint
SEQUEL Subanalysis: Annualized Incidence of Type 2 Diabetes at Wk 108
SEQUEL Subanalysis: Reduction of Type 2 Diabetes Incidence Related to Greater Weight Loss
SEQUEL Subanalysis: Design
Diabetes Pregnancy Guidelines Postpartum Care GDM | NDEI
Prediabetes Prevalence US Adults 2012 | NDEI
SCALE Obesity & Prediabetes Study Liraglutide Overweight Obesity | NDEI
SCALE Obesity & Prediabetes Trial Liraglutide GLP-1 Design PPT | NDEI
SCALE Trial FPG Liraglutide Vs Placebo in Obese Subjects PPT | NDEI
SCALE Obesity & Prediabetes Liraglutide Blood Pressure PPT | NDEI
SCALE Obesity & Prediabetes Trial Liraglutide Hypoglycemia PPT | NDEI
Weight Loss With Liraglutide 3 mg Obese With Prediabetes SCALE ENDO2015 | NDEI
Gut Microbiota & Glycemic Control ENDO2015 Diabetes PPT | NDEI
AACE 2015 Diabetes Guidelines Prediabetes Diagnosis IFG IGT PPT | NDEI
AACE 2015 Diabetes Guidelines Glucose Values Indicating Prediabetes PPT | NDEI
AACE 2015 Diabetes Guidelines Lifestyle Changes Diet Exercise PPT | NDEI
AACE 2015 Guidelines Hypertension Management PPT | NDEI
AHA ADA Diabetes Diagnosis Criteria Guidelines PPT | NDEI
Type 2 Diabetes Screening US Preventive Type 2 Diabetes Guidelines | NDEI
Blood Glucose Values Indicating Prediabetes or Type 2 Diabetes
Type 2 Diabetes Diagnostic Criteria US Preventive Guidelines | NDEI
Screening for Type 2 Diabetes & Prediabetes in Asymptomatic Individuals
Prediabetes Increases Type 2 Diabetes Risk ADA Guidelines | NDEI PPT
Type 2 Diabetes and Prediabetes Screening for Children ADA Guidelines | NDEI
ADA Obesity Management Guidelines in Patients With Type 2 Diabetes | NDEI
Type 2 Diabetes & Prediabetes Screening ADA Guidelines | NDEI PPT